News from eip pharma llc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 16, 2018, 07:00 ET EIP Pharma Secures $20.5 Million in Series B Financing

EIP Pharma, a therapeutics company focused on CNS diseases, today announced the successful completion of a $20.5 million Series B financing. The...


Mar 07, 2018, 08:00 ET EIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod

EIP Pharma LLC (www.eippharma.com), a CNS-focused therapeutics company, today announced that the results from a 3-month Phase 2a clinical study with...


Dec 08, 2016, 11:00 ET EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease

EIP Pharma, LLC (www.eippharma.com) today announced that it has obtained proof-of-mechanism for neflamapimod (previously code named VX-745), with the ...


Nov 16, 2016, 08:00 ET EIP Pharma announces upcoming oral presentations of Phase 2a clinical trial results with neflamapimod (VX-745) at Clinical Trials in Alzheimer's Disease (CTAD) conference Dec 8-10, 2016

EIP Pharma, LLC (www.eippharma.com) today announced that the results of each of two recently completed Phase 2a clinical trials of neflamapimod have...


Dec 16, 2015, 08:00 ET EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor

EIP Pharma LLC today announced the publication in the Journal of Alzheimer's Disease of an article entitled "Selective brain-targeted antagonism of...


Jun 24, 2015, 02:00 ET EIP Pharma kondigt eerste patiëntdosering aan in een klinische studie in Nederland van een nieuwe op de hersenen gerichte ontstekingswerende medicijnkandidaat voor de behandeling van de ziekte van Alzheimer

EIP Pharma LLC kondigde vandaag aan dat de eerste patiëntdosering is uitgevoerd in een fase-2 klinische studie van VX-745 aan het Alzheimer's...


Jun 03, 2015, 08:00 ET EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD)

EIP Pharma LLC (www.eippharma.com) today announced that patient dosing in phase 2 clinical development of VX-745 in Alzheimer's disease (AD) is...